MARKET

XCUR

XCUR

Exicure Inc
NASDAQ
13.64
+0.42
+3.20%
Opening 12:40 03/14 EDT
OPEN
14.00
PREV CLOSE
13.22
HIGH
14.79
LOW
13.61
VOLUME
37.32K
TURNOVER
--
52 WEEK HIGH
36.00
52 WEEK LOW
1.440
MARKET CAP
41.46M
P/E (TTM)
-6.0394
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 1d ago
Weekly Report: what happened at XCUR last week (0303-0307)?
Weekly Report · 4d ago
Weekly Report: what happened at XCUR last week (0224-0228)?
Weekly Report · 03/03 11:47
Weekly Report: what happened at XCUR last week (0217-0221)?
Weekly Report · 02/24 11:47
Weekly Report: what happened at XCUR last week (0210-0214)?
Weekly Report · 02/17 11:44
Weekly Report: what happened at XCUR last week (0203-0207)?
Weekly Report · 02/10 11:36
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 02/07 12:05
Weekly Report: what happened at XCUR last week (0127-0131)?
Weekly Report · 02/03 11:42
More
About XCUR
More
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.
Recently
Symbol
Price
%Change

Webull offers Exicure Inc stock information, including NASDAQ: XCUR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XCUR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XCUR stock methods without spending real money on the virtual paper trading platform.